Product Description
Perindopril is used alone or in combination with other medications to treat high blood pressure. Perindopril is in a class of medications called angiotensin-converting enzyme (ACE) inhibitors. It makes blood flow more smoothly by preventing the production of certain natural chemicals that tighten the blood vessels. (Sourced from: https://medlineplus.gov/druginfo/meds/a602017.html)
Mechanisms of Action: ACE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Myocardial Infarction | Hypertension | Stroke | Acute Myeloid Leukemia
Known Adverse Events: Dizziness | Headache | Edema
Company: Servier
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: COVID-19|Hypertension|Influenza, Human|Pneumonia
Phase 2: Cardiomyopathy, Hypertrophic
Phase 1: Acute Respiratory Distress Syndrome|Osteoporosis, Postmenopausal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REMAP-CAP | P3 |
Recruiting |
Pneumonia|Influenza, Human|COVID-19 |
2026-02-01 |
|
| 2020-004891-16 | P3 |
Active, not recruiting |
Hypertension |
2024-12-29 |
|
| BE-PER01-23 | P1 |
Recruiting |
Acute Respiratory Distress Syndrome |
2024-03-06 |
28% |
| PIA_PT_01 | P1 |
Recruiting |
Acute Respiratory Distress Syndrome |
2023-08-17 |
53% |